Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annu...(with acute lymphoblastic leukemia and a ...),Health

Date:12/3/2008

with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy and
'/>"/>

SOURCE Micromet, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Micromet, Inc. Reports Second Quarter 2008 Financial Results
2. Micromet, Inc. Reports First Quarter 2008 Financial Results
3. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
4. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
5. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
6. Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast
7. Thoratec Presentation at Piper Jaffary Conference to be Webcast
8. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
9. Medco to Webcast 2008 Analyst Day Conference
10. Leading Physicians To Host Medical Device Related Infection Prevention CME Webcast
11. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results